TITLE

DPP-4 Inhibitors

AUTHOR(S)
DICKER, DROR
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS276
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the impact of dipeptidyl peptidase 4 (DPP-4) inhibitors on glycemic control and cardiovascular risk factors. Examples of DPP-4 inhibitors include sitagliptin, glucophage, vildagliptin, linagliptin, alogliptin and saxagliptin. These inhibitors are different in their metabolism, excretion, recommended dosage and daily dosage that are required for effective treatment. Nasopharyngitis, upper respiratory tract infection and headache are the most commonly reported side effects of DPP-4 inhibitors.
ACCESSION #
61968024

 

Related Articles

  • Paper of the month.  // Pulse;Oct2013, p15 

    The article discusses the two placebo-controlled trials on the use of saxagliptin in type 2 diabetes patients at high risk of cardiovascular disease (CVD) and alogliptin in diabetics with acute coronary event, suggesting that gliptins do not affect CV outcomes.

  • The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus. Yousefzadeh, Pegah; Xiangbing Wang // Journal of Diabetes Research;2013, p1 

    Objective. To review the current literature investigating the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk factors of cardiovascular disease (CVD). Methods. We conducted a search of PubMed and MEDLINE database, using the term DPP-4 inhibitor in combination with the following...

  • Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Jang Won Son; Sungrae Kim // Diabetes & Metabolism Journal;Oct2015, Vol. 39 Issue 5, p373 

    Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability. Beyond their glucose-lowering effects, numerous clinical trials and...

  • Effect of Diets Differing in Glycemic Index and Glycemic Load on Cardiovascular Risk Factors: Review of Randomized Controlled-Feeding Trials. Kristo, Aleksandra S.; Matthan, Nirupa R.; Lichtenstein, Alice H. // Nutrients;Apr2013, Vol. 5 Issue 4, p1071 

    Despite a considerable amount of data available on the relationship between dietary glycemic index (GI) or load (GL) and cardiovascular disease (CVD) risk factors, in aggregate, the area remains unsettled. The aim of the present review was to summarize the effect of diets differing in GI/GL on...

  • Sweet SURRENDER`. Petty, Lisa // Alive: Canada's Natural Health & Wellness Magazine;Nov2014, Issue 385, p53 

    The article discusses how to treat the medical condition called insulin resistance which occurs when glucose is present in bloodstream and cells. It states reducing the consumption of sugar is the only option to preserve insulin and leptin sensitivity. It suggests consuming fresh raw fruits and...

  • In Vivo Actions of Peroxisome Proliferator-Activated Receptors. ELDOR, ROY; DEFRONZO, RALPH A.; ABDUL-GHANI, MUHAMMAD // Diabetes Care;Aug2013 Supplement, Vol. 36 Issue S2, pS162 

    The article examines the glycemic control, insulin sensitivity and insulin secretion by peroxisome proliferator-activated receptors (PPAR). The authors observed the beneficial effects of pioglitazone on glucose metabolism, insulin sensitivity, insulin secretion and cardiovascular risk factors...

  • Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Kim, Seoyoung; Glynn, Robert; Liu, Jun; Everett, Brendan; Goldfine, Allison // Acta Diabetologica;Dec2014, Vol. 51 Issue 6, p1015 

    Aims: Two recent randomized controlled trials of type 2 diabetes mellitus (T2DM) patients with history of, or at high risk of, cardiovascular disease (CVD) showed no risk of ischemic cardiovascular events associated with dipeptidyl peptidase-4 inhibitors (DPP4i), but an increased risk of heart...

  • Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.  // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p3 

    The article presents a research which examines the efficacy of cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin compared to comparator treatments in patients with type 2 diabetes mellitus (T2DM). It is reported that, the researchers used methods like,...

  • Low vs High Glycemic Index Diet. Brand-Miller, Jennie C.; Astrup, Arne; Buyken, Anette E. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1371 

    A letter to the editor is presented in response to the article "Effects of High Versus Low Glycemic Index of Dietary Carbohydrate on Cardiovascular Disease Risk Factors and Insulin Sensitivity: The OmniCarb Randomized Clinical Trial" by F.M. Sacks and colleagues published in a 2014 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics